Skip to main content
GutCited

Bifidobacterium longum para Irritable Bowel Syndrome (IBS)

B

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dlongum\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Conclusão

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

Key Study Findings

Meta-Analysis n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None vs: placebo Outcome: quality of life, depression, and anxiety in IBS … Efeito: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression) None

População: patients with irritable bowel syndrome

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None vs: placebo Outcome: improvement in key IBS symptoms Efeito: None None

População: patients with IBS from 32 RCTs evaluating 10 probiotic strains

In Vitro n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL vs: IBS supernatants without probiotic Outcome: Caco-2 paracellular permeability Efeito: None <0.001

População: IBS patients (28) and asymptomatic controls (7)

Review
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Dose: None vs: None Outcome: IBS symptom management via NLRP3 inhibition Efeito: None None

População: Patients with IBS (narrative review)

Controlled Clinical Trial n=51 12 weeks Open-label
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and …
Dose: None vs: Pre-treatment baseline Outcome: IBS-SSS score reduction Efeito: None None

População: IBS-D and IBS-C patients

Observational Study n=37 8 weeks Open-label
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms …
Dose: None vs: None Outcome: Total IBS symptom score (TISS) Efeito: 43.4% TISS reduction; >60% >=30% responders None

População: Adults with IBS (Rome IV criteria)

Key Statistics

4

Estudos

600

Participantes

Positive

B

Nota

Referenced Papers

Terapevticheskii arkhiv 2023 3 citações
The Cochrane database … 2020 14 citações
Journal of gastroenterology … 2017 32 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:
1-10 billion CFU/day
ibssupport:
1 billion CFU/day (35624 strain, marketed as Alflorex/Align)

Limite superior: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
None -- Positive 3154
None -- Positive --
1e6 CFU/mL -- Positive 35
None -- Positive --
None 12 weeks Positive 51
None 8 weeks Positive 37
1x10^10 CFU daily 6 weeks Positive 35
2 g 4 weeks Mixed --

Melhor horário: On an empty stomach or before meals

Safety & Side Effects

Efeitos Colaterais Relatados

  • Mild gas and bloating during initial use
  • Occasional abdominal discomfort
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

Interações Conhecidas

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

Ingestão máxima tolerável: Well-tolerated up to 10 billion CFU/day in clinical trials

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Bifidobacterium longum help with Irritable Bowel Syndrome (IBS)?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium longum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium longum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium longum?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium longum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.

Related Evidence

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.